What’s New and What’s Next in the Treatment of MDS?

What’s New and What’s Next in the Treatment of MDS?
What’s New and What’s Next in the Treatment of MDS?
CME, CPE, CNE
Mikkael A. Sekeres, MD, MS, and David P. Steensma, MD, FACP
Release Date: March 29, 2019
Expiration Date: March 29, 2020

MediCom Worldwide, Inc. is pleased to have collaborated with the MDS Foundation on the development of this activity. Myelodysplastic syndromes are a group of small-incidence malignancies that represent a significant challenge to many community oncologists. In this activity, participants will hear from two key experts about a variety of topics including, but not limited to: personalized risk stratification, iron overload, immunotherapies, and new strategies for treating lower- and higher-risk MDS. Join Dr. Sekeres and Dr. Steensma as they discuss incorporating molecular abnormalities into diagnosis and prognosis, and where luspatercept and imetelstat may fit into the future of MDS treatment.

For more information on managing your patients with MDS, please view the Newsletter Resource available here.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals and Celgene Corporation
CE ExpiredView Only, No Credit